-
Signature
-
Danielle White, Attorney-in-fact for Cyril Perducat
-
Stock symbol
-
ROK
-
Transactions as of
-
Dec 4, 2025
-
Transactions value $
-
-$56,004
-
Form type
-
4
-
Date filed
-
12/5/2025, 07:58 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Perducat Cyril |
SVP, Chief Technology Officer |
1201 SOUTH SECOND STREET, MILWAUKEE |
Danielle White, Attorney-in-fact for Cyril Perducat |
2025-12-05 |
0001862211 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ROK |
Common Stock |
Options Exercise |
$0 |
+465 |
+12.28% |
$0.00 |
4.25K |
Dec 4, 2025 |
Direct |
|
| transaction |
ROK |
Common Stock |
Options Exercise |
$0 |
+538 |
+12.65% |
$0.00 |
4.79K |
Dec 5, 2025 |
Direct |
|
| transaction |
ROK |
Common Stock |
Sale |
-$56K |
-139 |
-2.9% |
$402.91 |
4.65K |
Dec 5, 2025 |
Direct |
F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
ROK |
Restricted Stock Units |
Options Exercise |
$0 |
-465 |
-49.95% |
$0.00 |
466 |
Dec 4, 2025 |
Common Stock |
465 |
|
Direct |
F3, F4 |
| transaction |
ROK |
Restricted Stock Units |
Options Exercise |
$0 |
-538 |
-33.29% |
$0.00 |
1.08K |
Dec 5, 2025 |
Common Stock |
538 |
|
Direct |
F3, F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: